302 related articles for article (PubMed ID: 24492943)
1. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
[TBL] [Abstract][Full Text] [Related]
2. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
Gao W; Kim H; Ho M
PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
[TBL] [Abstract][Full Text] [Related]
3. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.
Li N; Wei L; Liu X; Bai H; Ye Y; Li D; Li N; Baxa U; Wang Q; Lv L; Chen Y; Feng M; Lee B; Gao W; Ho M
Hepatology; 2019 Oct; 70(4):1231-1245. PubMed ID: 30963603
[TBL] [Abstract][Full Text] [Related]
4. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
Lai JP; Oseini AM; Moser CD; Yu C; Elsawa SF; Hu C; Nakamura I; Han T; Aderca I; Isomoto H; Garrity-Park MM; Shire AM; Li J; Sanderson SO; Adjei AA; Fernandez-Zapico ME; Roberts LR
Hepatology; 2010 Nov; 52(5):1680-9. PubMed ID: 20725905
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.
Fleming BD; Ho M
Toxins (Basel); 2016 Sep; 8(10):. PubMed ID: 27669301
[TBL] [Abstract][Full Text] [Related]
6. WNT/β-catenin signaling and hepatocellular carcinoma.
Wands JR; Kim M
Hepatology; 2014 Aug; 60(2):452-4. PubMed ID: 24644061
[No Abstract] [Full Text] [Related]
7. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
[TBL] [Abstract][Full Text] [Related]
8. Both glypican-3/Wnt/β-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma.
Hu P; Ke C; Guo X; Ren P; Tong Y; Luo S; He Y; Wei Z; Cheng B; Li R; Luo J; Meng Z
Dig Liver Dis; 2019 Jan; 51(1):120-126. PubMed ID: 30001951
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy.
Bi Y; Jiang Y; Li X; Hou G; Li K
J Cancer Res Clin Oncol; 2021 Feb; 147(2):499-505. PubMed ID: 33225417
[TBL] [Abstract][Full Text] [Related]
10. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
[TBL] [Abstract][Full Text] [Related]
11. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
[TBL] [Abstract][Full Text] [Related]
12. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
[TBL] [Abstract][Full Text] [Related]
13. Glypican-3: a new target for cancer immunotherapy.
Ho M; Kim H
Eur J Cancer; 2011 Feb; 47(3):333-8. PubMed ID: 21112773
[TBL] [Abstract][Full Text] [Related]
14. Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma.
Xia L; Teng Q; Chen Q; Zhang F
Int J Nanomedicine; 2020; 15():2197-2205. PubMed ID: 32280214
[TBL] [Abstract][Full Text] [Related]
15. Propofol-induced miR-219-5p inhibits growth and invasion of hepatocellular carcinoma through suppression of GPC3-mediated Wnt/β-catenin signalling activation.
Gong T; Ning X; Deng Z; Liu M; Zhou B; Chen X; Huang S; Xu Y; Chen Z; Luo R
J Cell Biochem; 2019 Oct; 120(10):16934-16945. PubMed ID: 31104336
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling.
Capurro M; Martin T; Shi W; Filmus J
J Cell Sci; 2014 Apr; 127(Pt 7):1565-75. PubMed ID: 24496449
[TBL] [Abstract][Full Text] [Related]
18. Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma.
Yu L; Huang N; Sun H; Yang X; Fu Y; Lang Q; Wang J; Ge L
J Immunother; 2021 Apr; 44(3):106-113. PubMed ID: 33239522
[TBL] [Abstract][Full Text] [Related]
19. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
[TBL] [Abstract][Full Text] [Related]
20. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
